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1. Introduction 
As it has been mentioned in the previous chapters, Angina pectoris, commonly known as 
angina, is severe chest pain and discomfort due to myocardial ischemia. A lack of blood, 
hence a lack of oxygen supply for heart muscle, will cause this pain which can be because of 
narrowed and blocked coronary arteries. In other words, angina can be assumed to play the 
role of a protective mechanism to signal myocardial ischemia.  
There are different kinds of angina. Stable, unstable, Prinzmetal’s or variant angina and 
latterly discovered type called microvascular angina which is caused by small blood vessels, 
not artery damage. 
Although the amount of mortalities and morbidities of heart diseases and additionally the 
diagnostic techniques in this field underwent drastic improvements, still there are many 
patients complaining about angina pectoris mostly as a restricting pain. Due to the report of 
American Heart Association statistics committee and stroke statistics subcommittee in 2010, 
the prevalence of angina pectoris has become 9.8 million, translating to almost 30 thousand 
per million. This amount in Europe has been estimated to be around 20 - 40 thousand per 
million (Fox, Garcia et al. 2006; Fernandez, Tandar et al. 2010; Lioyd-Jones, Adams et al. 
2010). In another study performed in US, it has been mentioned that 1 in 4 patients is 
experiencing angina pectoris following myocardial infarction. With regard to the annual 
occurrence of MI in US which is 1.5 million cases, there are significant amount of people in 
each year suffering from angina. Therefore, curing angina pectoris is of high importance 
(Plomondon, Magid et al. 2007).  
Although one of the main goals in angina treatment is relief of symptoms, amelioration of 
the position, especially pain, will unexpectedly cause the ischemia to proceed and so, the 
consequence will be cardiac injury. Considering this problem, due to American and 
European drug regulators the anti-anginal medicines also needs to possess anti-ischemia 
effects, as well. Other purposes of angina pectoris treatment are slowing progression of the 
disease and reduction of future events, especially heart attacks and, of course, death by 
treating the underlying heart condition. Treatments for angina include lifestyle changes, 
medicines, medical procedures, cardiac rehabilitation, and other therapies and will depend 
on the severity of the symptoms, severity of the underlying disease, and extent of damage to 
the heart muscle, if any (Parker and Parker 2002; Fernandez, Tandar et al. 2010). 
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In recent decades, pharmaceutical scientists focus has been on design of systems which can 
manage to release the medication with a steady or a controlled speed. These delivery 
systems are called "novel".  
The application of novel drug delivery systems in angina therapy show their importance 
through controlling release of a medication with short therapeutic index or decreasing the 
drug dosage intervals which can increase patients' compliance in following up the therapy 
or even it can control the release of drug according to the chronobiology  (Dehghan, 
Aboofazeli et al. 2010; Mandal, Biswas et al. 2010).  
In this chapter, medications and pharmacotherapy of angina pectoris will be mainly 
discussed. At the end of chapter one will be informed of conventional and novel 
medications for treatment of angina. 
2. Anti-angina currently used medicines 
In angina therapy drugs are playing an important role. A variety of medicines with different 
dosage forms and amounts are prescribed in each type of angina. Since the main cause of 
angina is lack of oxygen supply in the coronary arteries, the anti-anginal agents usually play 
their roles through increasing oxygen delivery or decreasing oxygen requirement of the 
tissue or both. Obviously, ascending the amount of oxygen delivery is possible with 
vasodilation and reduced oxygen demand can be caused by cardioinhibitors which reduce 
heart rate and contractility. There are still other mechanisms that may occur in treating 
angina pectoris. For instance, anti-thrombotic drugs which avoid formation of thrombus, 
like anticoagulants, are involved in angina therapy. Figure 1 shows a schematic 
classification of conventional anti-anginal medications. 
Regularly, in angina pharmacotherapy, medications are prescribed for three different 
purposes. 1) To reduce the number of angina attacks by daily use of certain drugs over a  
 
 
 
 
 
Fig. 1. Conventional medicines used in treatment of angina pectoris 
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long period. 2) To prevent attacks before some exercises or robust activities. 3) To relief the 
pain and pressure of an attack when it begins. 
Generally, there are five main types of medicines, which help to relief, control symptoms 
and increase blood flow and oxygen supply to the heart muscle:  
 Nitrates  
 Beta-blockers  
 Calcium channel blockers  
 Anti-platelets 
 Statin drugs  
Moreover, due to the patient's condition, other medications can be prescribed by the 
specialist, as well. And also these drugs can be prescribed in combination which in most 
cases it works more efficiently than monotherapy. 
2.1 Nitrates and nitrites  
Here the term "nitrates" is taken to include both nitrates and nitrites avoiding repetition. But 
it is presumed that the nitrates can only reduce to nitrites for exerting their action. 
Nitrates are one of the oldest medications for angina. They are potent vasodilators that open 
up the arteries, improving blood flow to the body (including heart) which raises the oxygen 
supply of myocardium.  There are two kinds of nitrates: short acting nitrate preparation and 
long acting nitrate preparation. Short acting ones usually are used to ease angina pains 
and/or to prevent developing an anginal attack before an exercise that is likely to cause one. 
Whilst the long acting productions are prescribed in a regular daily basis for the patients 
with frequent anginal pains and it is not useful for rapid pain relief. 
The most important drug of this group is Nitroglycerin (glyceryl trinitrate) which was the 
first medication used in 1879 by William Murrell for the treatment of angina pectoris and, its 
immediate release forms, still remains the therapeutic mainstay for patients suffering from 
classic and variant angina. Nitroglycerin is often administered sublingually for rapid relief 
of angina sudden attack (Murrell 1879). The main drugs of this group include: nitroglycerin 
or glyceyl trinitrate (GTN), isosorbide dinitrate, isosorbide mononitrate, pentaerythritol 
tetranitrate (PETN) and amyl nitrite. 
2.1.1 Mechanism of action 
Nitrates in the smooth muscle of both venous and arterial beds, are denitrated into nitric 
oxide (NO) which is a potent vasodilator. This vasodilatation relieves anginal pain through 
different mechanisms. Veins dilation will reduce cardiac workload and consequently, 
oxygen demand. Coronary dilation will increase blood flow to ischemic areas. And finally 
dilation of arterioles will lower the afterload and so cardiac workload. 
The released NO from nitrates activates guanylate cyclase and increases the amount of 
cyclic guanine monophosphate (cGMP). cGMP which is a second messenger, activates 
protein kinase. Myosin light chains dephosphorylate by protein kinase. As a result, the 
smooth muscle becomes relaxed. Additionally, decreased intracellular calcium levels by 
cGMP are another mechanism of smooth muscle relaxation (Katzung, Masters et al. 2009). 
2.1.2 Pharmacokinetics 
The nitrates undergo first-pass effect in liver excluding isosorbide mononitrate. Thus, 
despite their high absorption from the GI, nitrates absorption into the systemic circulation is 
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incomplete; i.e., oral preparations have slow onset of action (except sublingual tablets) 
which is not pleasant when quick relief is required. So, there are available dosage forms 
with short onset time. 
Nitrates distribute extensively throughout the body and their bonding to plasma protein has 
been estimated to be around 60%.  
Nitrates undergo metabolism in liver by the enzyme glutathione organic nitrate reductase. 
For example the yielded active metabolites for nitroglycerin are glyceryl dinitrates and 
mononitrates. 
The metabolites of nitrates are excreted in urine, except isosorbide moninitrate, that less 
than 1% of it is eliminated in urine. Elimination half-lives of nitrates differ depending on the 
kind of nitrate and administration route. Table 1 indicates elimination half-lives of some 
preparation of nitrates. 
2.1.3 Adverse reactions 
Acute side effects: Throbbing headache and dizziness are the most common side effect of 
nitrates (these are probably consequences of blood vessles vasodilation). Orthostatic 
hypotension is another common side effect of using nitrates. There is a rare situation named 
"nitrite syncope". In which the nitrate-induced hypotension is severe and thus, the lowered 
blood pressure will cause slowing of heart rate, nausea, shivering and syncope. The adverse 
effects of gastrointestinal tract include nausea and vomiting. 
Nitrate tolerance: Continuous uptake of nitrates (any kind) in high dose may cause tolerance. 
In tolerance, the nitrate's effect will become weak or disappear completely. Although, the 
mechanism of tolerance has been poorly understood but diminished amount of nitric oxide 
and systemic compensation can be partly responsible for this phenomenon. The well-known 
so called "Monday disease" is a touchable example of nitrate tolerance that has happened in 
industries, especially where explosives are manufactured(Rutherford 1995; Munzel, Daiber 
et al. 2005).  
2.1.4 Dosage forms 
According to different indications of nitrates, considering two main groups of long- and 
short- acting nitrates, there are a wide range of preparation forms to fulfill the patients' 
demands (table 1). 
Short acting and long acting anti-anginal agents are being prescribed due to their onset 
and duration of action. For rapid cardiac response, nitroglycerin formulations with short 
onset (sublingual tablets or pump sprays) are administered. At the commencement of an 
attach, exactly when the patient starts to feel the chest pain or before starting an activity, 
one 0.3 or 0.4 mg pill or one metered dose of spray can be taken and patient can repeat it 
every 5 minutes, if necessary, up to maximum three doses. These dosage ranges for 
isosorbide dinitrate is fairly different. In this case, sublingual 2.5 to 10 mg tablets should 
be taken. The repetition dose is every 2-3 hours during acute phase and 4-6 hours for 
prophylaxis. 
Long acting nitroglycerin sustained-release tablets are prescribed 2.5-13 mg every 6-12 
hours. Alternatively, the topical form or the patches can be used instead. Isosorbide dinitrate 
extended-release formulations are administered 40-80 mg twice daily. 
In any case, it is necessary to have 10-12 hours nitrate-free interval per day due to 
prevention of nitrate tolerance (Cutler, Eff et al. 1995; Katzung, Masters et al. 2009). 
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Kind of nitrate Dosage form 
Amount of active 
agent 
Elimination 
half-life 
Nitroglycerin 
Tablets (sublingual) 0.15, 0.3, 0.4 and 0.6 mg 1/2–1 hr 
Tablets (buccal and 
controlled-release) 
1, 2 and 3 mg 3-5 hr buccal 
Capsules 
(sustained-release) 
2.5, 6.5, 9 and 13 mg 5 hr 
Aerosol (lingual) 0.4 mg/metered spray 1/2–1 hr 
I.V. 0.5, 0.8 and 5 mg/ml 3-5 min 
I.V. premixed 
solutions in 
dextrose 
100, 200 and 400 
mcg/ml 
 
Topical 2% ointment 2-12 hr 
Transdermal 
(patches) 
0.1, 0.2, 0.4, 0.6 and 0.8 
mg/hour systems 
24 hr 
Isosorbide dinitrate 
Tablets 5, 10, 20, 30 and 40 mg 5-6 hr 
Tablets (sublingual) 2.5, 5 and 10 mg 1/2–2 hr 
Tablets  
(extended-release) 
40 mg 5-6 hr 
Tablets (chewable) 5 and 10 mg 1/2–2 hr 
Capsules 
(extended-release) 
40 mg 5-6 hr 
Isosorbide 
mononitrate 
Tablets 10 and 20 mg Unknown 
Tablets  
(extended-release) 
30, 60 and 120 mg  
Amyl nitrite 
Solution 
(inhalation) 
50 mg 5 min 
Table 1. Commercialized dosage forms of nitrates (Christensen, Comerford et al. 2003). 
2.2 Beta blockers 
Beta blockers have been used for over 35 years to treat both angina and high blood pressure 
(hypertension). These medications through beta blockade slow the heart rate, decrease 
blood pressure, and lessen the force of contraction of the heart muscle, however, the third 
generation of beta blockers show to have vasodilatory effects through different pathways 
which will be discussed more in section 2.2.1. When taken regularly, beta-blockers are 
proven to prevent heart attacks and mortality and reduce the frequency of angina attacks 
(reinfarction). Because of their effects on the respiratory system, beta-blockers are unsuitable 
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for angina sufferers who have asthma or bronchitis.  Carvedilol, propranolol and atenolol 
are some of most important beta blockers. 
2.2.1 Mechanism of action 
There are three types of beta receptors in the body that control several different functions. 
Beta-1 receptors are located mostly in heart muscle and also in eye and kidneys, whilst the 
prominent part of beta-2 receptors are in upper respiratory system (bronchial vascular 
smooth muscle); however, there are a few beta-2 receptors in heart muscle. And finally beta-
3 receptors are distributed in adipose tissue. The beta receptors are targets of 
cathecolamines, especially noradernaline (norepinephrine) and adernaline (epinephrine). In 
fact, beta blockers induce their effect by preventing the normal ligand (cathecolamines) from 
binding to beta receptors. Due to their distribution sites in body, beta-1 and beta-2 blockers 
are of interest in angina therapy. Preventing adrenaline's performance on heart by beta 
blockers causes lower heart rate, contractility and blood pressure and in one words reduced 
heart's workload. Thus, the myocardial oxygen demand will decrease and this final effect is 
assumed to be the most important effect of beta blockers in angina treatment. The final 
function of beta blockers owing to their ability to be selective or nonselective, cause them to 
have different indications. The nonselective beta antagonists, blockade both beta-1 and beta-
2 receptors, whereas, the selective ones only block beta-1 receptors (cardioselective beta 
blockers). These two groups of agents that are used in angina pharmacotherapy are listed in 
table 2, seperately. 
 
Nonselective Beta blockers 
useful in angina treatment 
Selective Beta blockers 
useful in angina treatment 
Carvedilol Acebutolol 
Labetalol Atenolol 
Nadolol Betaxolol 
Penbutolol Bisoprolol 
Pindolol Metoprolol 
Propranolol  
Timolol  
Table 2. Selective and nonselective anti-anginal beta blockers 
As it was mentioned before, the third generation of beta-adrenoceptor antagonists 
comprises drugs with extra ability of vasodilatation. Most of them play their role by 
blocking alpha-1 receptor (labetalol, carvedilol and bucindolol). Nebivolol is the exception 
of third generation; because, the vasodilatation mechanism of this beta-1 highly selective 
blocker is by stimulating nitric oxide release (Weiss 2006; Karter 2007). 
2.2.2 Pharmacokinetics 
Most of beta blockers are quickly absorbed after oral administration (generally from small 
intestine). Moreover, their systemic absorption after topical application has been confirmed 
to be without significant delay. However, there are pharmacokinetical differences in the 
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drugs of this category which is mostly because of their hydrophilic or lipophilic affinities. 
For example the absorption of hydrophilic beta blockers such as nadolol and atenolol from 
GI is incomplete. Furthermore, this characteristics influence beta blockers indications, as 
well. Since, the lipophilic beta antagonists can pass blood brain barrier and enter CNS 
(propranolol), they are used in prophylactic treatment of migraine or vascular headache.  
Beta adrenoceptor antagonists' distribution in body is also influenced by this quality. The 
lipophilic beta blockers are more detected in biologic fluids. 
Due to solubility of beta blockers in water or lipid, their metabolism and elimination can be 
through liver or kidneys; i.e. drugs with low lipophilicity are excreted from kidneys, whilst 
more lipophilic substances are metabolized in liver.  
2.2.3 Adverse reaction 
Beta blockers are widely prescribed throughout the world in several remedies and they do 
not seem to have many severe side effects. Nevertheless, their most important unpleasant 
effects are due to inhibitory effect of nonselectives on beta-2 receptors. Since beta-2 receptors 
are mainly in bronchi, beta-2 antagonists hinder opposing the alpha 1 receptor-mediated 
vasoconstructor tone. Thus the patients with any dysfunction in their airways will 
experience serious problems. To overcome this disadvantage, new class of beta blockers 
with beta-1 selectivity and partial beta-2 agonist ability, has emerged. Beta-1 antagonists are 
preferable to the prior beta blockers, however, since bronchospasm was reported in certain 
individuals followed by selective beta blockers uptake, they are not considered completely 
"safe". 
Other adverse effects experienced by the patients are dizziness and lightheadedness 
accompanied by blurred vision. Some people may feel cold in their hands and feet as a 
result of decreased blood pressure, especially to the extremities. Moreover, beta blocker 
consumption may cause some allergic reactions like rashes and itching. 
2.2.4 Dosage forms 
Available formulations of beta blockers have been summarized in table 3. 
Among these drugs, betaxolol, bisoprolol, nadolol and penbutolol are prescribed for angina 
prophylaxis, while others are used in treatment of angina attacks.  
 
 
Generic name of 
beta receptor 
antagonist 
Dosage form 
Amount of active 
agent 
Dosage range 
Acebutolol Capsules 200 & 400 mg 
200 mg twice daily 
up to 800 mg and 
even higher, if 
necessary 
Atenolol Tablets 25, 50 & 100 mg 
50 mg once daily 
and can be adjusted 
after one week. 
Maximum daily 
dose is 200 mg 
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Generic name of 
beta receptor 
antagonist 
Dosage form 
Amount of active 
agent 
Dosage range 
Betaxolol 
Tablets (film-
coated) 
10 & 20 mg 
10-20 mg once a 
day. Can be 
increased to 50 
mg/day after one or 
two weeks of 
inadequate response 
Bisoprolol Tablets 
 
5 & 10 mg 
5 mg per day, can be 
increased every 
three days, up to 20 
mg 
Carvedilol Tablets  
Started with 6.25mg 
twice a day and can 
be continued up to 
50mg per day 
Labetalol 
(Quyyumi, Wright 
et al. 1985) 
Tablets  
(film-coated) 
100, 200 & 300 mg  
Metoprolol 
Tablets 50 & 100 mg 
100 to 400 mg in 
divided doses 
Tablets  
(extended-release) 
25, 50, 100 & 200 
mg 
100 to 400 mg daily 
Nadolol Tablets 
20, 40, 80, 120 & 160 
mg 
40 mg per day. Can 
be increased up to 
even 240 in certain 
time intervals 
Penbutolol Tablets 20 mg 20-40 mg once a day 
Pindolol Tablets 5 & 10 mg 
15 to 40 mg divided 
doses per day 
Propranolol 
Capsules 
(extended-release) 
60, 80, 120 & 160 
mg 
Tablets or solution 
can be administered 
40-320 mg in three 
or four doses daily 
and the long-acting 
forms are given 
once a day, 
however, it can 
increase 
Tablets 
10, 20, 40, 60 & 80 
mg 
Solution 4, 8 & 80 mg/ml 
Timolol Tablets 5, 10 & 20 mg 
10-30 mg twice 
daily(Arronow, 
1980) 
Table 3. Beta blockers dosage forms which are used as anti-anginal agents (Christensen, 
Comerford et al. 2003) 
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2.3 Calcium channel blockers (CCBs) 
Calcium channel blockers, also called slow calcium channel antagonists or slow channel 
blockers, inhibit calcium ion movement through slow channels in cardiac and smooth 
muscles. CCBs are mostly used for treatment of classic and variant angina. Also, they are 
particularly beneficial if angina is caused by arterial spasms (Prinzmetal's variant angina) 
rather than blockage.  
Drugs of this category are classified into two classes, dihydropyridines (DHPs) and non-
dihydropyridines (non-DHPs). The non-DHPs are again comprises of three further 
compounds: phenylalkylamines, benzothiazepines and tertralols (Ryman and Gurk-Turner 
1999). The most selective calcium channel blockers belong to dihydropyridines.  
2.3.1 Mechanisms of action 
CCBs blockade the calcium ion influx into vascular smooth muscle cells and cardiac 
myocytes across the voltage gated slow channels. Thus the intracellular calcium levels will 
diminish. Since, the most important ion for muscle contractility is assumed to be calcium, as 
a result of decreased calcium levels, vasodilatation of both coronary and peripheral arteries 
and lower cardiac conduction will be observed. Vasodilatations will cause low blood 
pressure and consequently, less heart afterload and oxygen demand. 
2.3.2 Pharmacokinetics 
CCBs are usually well absorbed following oral administration, although they can have 
different bioavailability due to their metabolism.  
They are widely distributed in body fluids with a high protein-binding affinity. It is proved 
that protein binding percentage of dihydropyridines is higher than non-dihydropyridines. 
Most of Calcium channel blockers are metabolized and cleared hepatically and less than 5% 
is secreted unchanged in urine. And some of them undergo extensive first-pass metabolism 
which will influence drug's plasma level and half life. Thus, it should be taken into account 
in dose adjustment. 
Elimination half-lives of old CCBs are rather short (3-8 hours), whereas the newer ones (esp. 
new DHPs) have been designed to last longer in body (Opie 1989; Piepho 1991). 
2.3.3 Adverse reactions 
Generally, the side effects of CCBs are not really common but still the incidence of some 
adverse reactions has been reported in a number of patients. Peripheral vasodilatation 
accounts for the major side effects of DHPs like flushing, headache, rashes, excessive 
hypotension, peripheral edema (esp. Pedal edema) and palpitation (reflecting reflex 
tachycardia) (Sirker, Missouris et al. 2001). The later effect is the reason that most of DHPs 
are not preferred in treatment of angina pectoris.  
Non-DHPs side effects are mostly because of the muscle relaxation effect; for instance, they 
can cause severe bradycardia, or can influence electrical conduction system of heart. This 
relaxation in smooth muscles of intestine and colon may cause constipation. Constipation is 
followed by verapamil administration.  
2.3.4 Dosage forms 
Two main classes of slow channel blockers, have different mode of actions and thus, diverse 
indications. Although all calcium channel blockers seem to be effective in treatment of stable 
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angina, causing reflex tachycardia, the dihydropyridines usually are not administered for 
this purpose. The only FDA approved DHPs as the treatments for angina are nifedipine, 
amlodipine, nicardipine and biperidil of which nifedipine and amlodipine are used in both 
vasospastic and chronic stable angina, while biperidil and nicardipine's application is 
limited to just chronic stable angina (Ryman and Gurk-Turner 1999; Helms, Quan et al. 
2006). Table 4 displays dosage forms of some CCBs which are used in angina therapy. 
Mibefradil, of tertralol subgroup, was used as an anti-anginal agent but was withdrawn 
from the market because of serious interactions with other drugs. 
 
 
Dihydropyrodines 
Generic name 
of beta 
receptor 
antagonist 
Dosage form Amount of active 
agent 
Dosage range 
Amlodipine Tablets 2.5, 5 & 10 mg 5-10 mg daily 
Nicardipine Capsules 20 & 30 mg 20-40 mg three times 
a day 
Nifedipine Capsules 10 & 20 mg 10-20 mg three times 
a day, can increase 
due to patients 
position 
Tablets (extended-
release) 
30, 60 & 90 mg 30 to 60 mg once 
daily 
Bepridil Tablets (film-coated) 200 & 300 mg 200 up to maximum 
400 mg daily 
Non-dihydropyridines   
Generic name 
of beta 
receptor 
antagonist 
Dosage form Amount of active 
agent 
Dosage range 
Diltiazem Tablets 30, 60, 90 & 120 mg Start with 30 mg three 
times a day and can 
be increase up to 360 
mg divided doses per 
day 
 Capsules (extended-
release) (Containing 
multiple 60-mg units of 
diltiazem) 
120, 180 & 240 mg 120-480 mg once 
daily(Cutler, 1995) 
 Capsules (sustained-
release) 
60, 90, 120, 180, 240, 
300, 360 & 420 mg 
 
Verapamil Tablets 40, 80 & 120 mg  
 Tablets 
(sustained-release and 
extended-release) 
120, 180 &240 mg  
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 Capsules 
(sustained-release) 
100, 120, 180, 
200,240, 300 
& 360 mg 
 
 Capsules 
(extended-release) 
120, 180 & 240 mg  
Table 4. Calcium channel blockers administered in angina therapy (dosage forms and 
dosing ranges) (Christensen, Comerford et al. 2003)  
2.4 Anti-platelets   
These anti-thrombotic drugs prevent platelet clumping and so thrombus formation in blood 
circulation. There are several subgroups of antiplatelets such as: cyclooxygenase inhibitors, 
adenosine diphosphate (ADP) receptor inhibitors (contains thienopyridines), glycoprotein 
IIB/IIIA inhibitors and adenosine reuptake inhibitors. Anti-plateletes, dislike anti-
coagulants, have the most anti-clot effect in arterial circulation. Since aspirin and clopidogrel 
are this group's mainly prescribed drugs in angina, in this section they will be discussed in 
details. Ticlopidine is another thienopyridine that has been shown to have effects on 
treatment of unstable angina. But according to the results of some studies, ticlopidine have 
more adverse effects than clopidogrel (Hankey, Sudlow et al. 2000). 
Aspirin has clot-preventing properties within the coronary arteries or other blood vessels. 
Daily aspirin therapy is advised to patients, unless they have problems tolerating it. In this 
case, clopidogrel can be used instead. However, one recent study showed that in patients 
suffering stable angina, treatment with aspirin and clopidogrel indicates greater platelet 
formation blockade rather than monotherapy with aspirin alone (Saha, Berglund et al. 2008). 
2.4.1 Mechanism of action 
Since aspirin has many indications, it can act through different biologic pathways. Aspirin 
anti-platelet and with less importance anti-inflammatory effects are believed to be the main 
mechanisms in treating angina pectoris. 
Anti-platelet and anti-inflammatory: While administered in low doses, aspirin inhibits 
prostaglandin synthetase action and therefore avoid clotting followed by preventing 
thromboxane A2, the platelet-aggregating substance, formation. Aspirin owes this ability of 
prostaglandins and thromboxanes suppression to irreversible inactivation of the 
cyclooxygenase (COX) enzyme. As the chemical structure of aspirin can be observed in fig.2, 
its free acetyl group is attached to a serine residue in the active site of COX enzyme through 
a covalent bond. This is the reason of difference between aspirin and the similar anti-
inflammatory NSAIDs group which are reversible inhibitors.  
Although if the dose of aspirin rises, it will interferes with prostacyclin production and so 
this will negate the anticlotting properties.   
The exact mechanism of aspirin's anti-inflammatory action is not completely understood but 
it is mostly believed that the ability to inhibit prostaglandin synthesis can influence 
synthesis or action of other mediators of inflammation by restraining them. 
Clopidogrel is a selective adenosine diphosphate (ADP) antagonist. It irreversibly blocks the 
ADP receptor on the platelet cell membrane and consequently the glycoprotein IIb/IIIa 
cannot be activated and so platelet aggregation will be avoided (Savi, Nurden et al. 1998).  
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Fig. 2. Chemical structure of aspirin 
2.4.2 Pharmacokinetics 
Since aspirin is a weak organic acid with a pKa equal to 3.5, in oral dosage form it is 
expected to absorb in stomach and proximal small intestine in nonionized form; because in 
these areas the acidic environment dominates.  
Suddenly after absorption it is metabolized into acetic acid and salicylate. This rapid 
metabolism is resulting in high concentrations of salicylates in most body liquids and fluids. 
Therapeutic salicylate blood level for anti-inflammatory effect is 150 to 300 mcg/ml. Salicylates 
have rather high protein binding ranged from 75 to 90% depending on blood level. 
Salicylate is excreted by the kidneys with first-order kinetics and its elimination half-life has 
estimated to be between 2 and 4.5 hours depending on the aspirin administered dose (in 
toxic doses this range reaches 15 to 30 hours) (Hartwig-Otto 1983). 
Clopidogrel is a prodrug and after rapid oral absorption, it is converted to the active agent 
in liver. The half life of this active agent is 8 hours.  
Clopidogrel is eliminated almost equally from urine and feces.  
2.4.3 Adverse reactions 
One of the main adverse effects of aspirin is gastric upset. Especially when taken in high 
doses the risk of gastrointestinal bleeding increases. Aspirin uptake can be also 
accompanied by nausea and heartburn. 
The patient taking aspirin is advised to be monitored frequently; the main reason is because 
it may cause leucopenia, thrombocytopenia and prolonged bleeding time. 
Other rare but severe side effects include Rey's syndrome, anaphylaxis and angioedema. 
Some of clopidogrel's side effects are neutropenia, hemorrhage and skin rash. 
2.4.4 Dosage forms 
There are several dosage forms of these medications available in the market. As aspirin is 
considered to be multifunctional, the only forms that can be used in treatment of angina are 
in table 5. 
2.5 Statins  
Statins or HMG CoA reductase inhibitors, lower cholesterol and have been shown to 
stabilize the fatty plaque on the inner lining of the coronary artery, even when the blood 
cholesterol is normal or minimally increased.  Due to recent research statins can 
atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin (Dehghan, Aboofazeli et al. 
2010; Dvir and Battler 2010). 
2.5.1 Mechanisms of action 
Since hyperlipidemia has been proved to be one of the main reasons for coronary heart 
diseases, lowering lipid levels in bloods can decrease the incidence of cardiovascular 
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disease. The most effective impact of statins on the patients suffering from anginal attacks is 
believed to be through lowering the LDL cholesterol level in plasma (Khan 2006). 
HMG CoA reductase is an enzyme responsible for mevalonate production. In lipid forming 
pathway, mevalonate is finally transformed to cholesterol. Statins which have some 
structural similarities with this HMG CoA, can competitively attach to the enzyme and 
block it. Therefore, the speed of cholesterol biosynthesis will decline. Statins play their role 
in angina therapy through other mechanisms, as well.  
Researchers have defined some other modes of actions for statins, rather than lipid 
lowering, in managing heart related diseases like anti-inflammatory, plaque stability and 
prevention of clotting. These beneficial effects are independent from lipid lowering 
characteristics (Furberg 1999). 
 
Name Drug Form Amount of Active Agent Dosage Ranges 
Aspirin Tablets 81 and 325 mg  
Prevention doses: 81 
to 325mg daily or 
every other day; 
Treatment doses: 160 
to 325mg once daily 
 
 
 
 
 
Tablets 
(enteric-coated) 
81, 100, 162, 165 and 325 mg 
 
Tablets 
(chewable) 
81 and 100 mg 
 
Tablets 
(effervescent) 
100 mg 
 Suppositories 120, 125, 200 and 300 mg 
Clopidogrel Tablets 75 mg 75 mg once a day 
Table 5. Available dosage forms of aspirin and clopidogrel for angina treatment 
2.5.2 Pharmacokinetics 
The pharmacokinetic characteristics of statins vary widely due to their different structures 
which determine their water or lipid solubility. Quite lipophilic statins are atorvastatin, 
simvastatin, lovastatin, fluvastatin, cerivastatin and pitavastatin; whereas pravastatin and 
rosuvastatin are relatively hydrophilic. Obviously, the lipophilic compounds have rapid 
absorption and distribute easily in biologic fluids. 
Almost all of lipophilic statins are metabolized hepatically by cytochrome P450 enzymes 
and due to their efficient first-pass effect their bioavailability varies from 5% to 60%. Whilst, 
the hydrophilic statins have longer half lives and excreted both through liver and kidneys. 
HMG CoA reductase inhibitors have half lives ranged from less than 5 hours in simvastatin 
up to 22 hours in pravastatin and 20 – 30 hour in some metabolites of atorvastatin (Garcia, 
Reinoso et al. 2003; Schachter 2004). 
2.5.3 Adverse reactions 
Although statins considered being among the safest drugs, the most important but 
infrequent side effect of statins is because of their metabolism pathway (cytochrome P450) 
which can cause myopathy and hepatotoxicity and of course serious interactions with other 
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substances. Myopathy appears as pain and weakness in muscles and rarely rhabdomyolysis. 
One of statins called cerivasatin was withdrawn from the market due to fatal 
rhabdomyolysis reports, in 2001. 
Other side effects address the liver. Statins can increase amount of hepatic enzymes. This 
increase, if severe, will cause liver damage. Therefore, the medication can be changed to 
another statin.  
2.5.4 Dosage forms 
Atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin are frequently 
prescribed as treatments of angina pectoris. More information about the different 
formulations and dosage of these drugs can be found in table 6.  
 
Generic 
name of beta 
receptor 
antagonist 
Dosage form 
Amount of active 
agent 
Dosage range 
Atorvastatin 
Tablets 
(film-coated) 
10, 20, 40 & 80 mg 
Starting with 10-40 mg once a 
day, can be increased up to 80 
mg daily for maintenance dose 
Fluvastatin Capsules 20 & 40 mg 20 to 80 mg divided doses 
 
Tablets 
(extended- 
release) 
80 mg 80 mg once a day 
Pravastatin Tablets 10, 20, 40 & 80 mg 
Usually 40 or 80 mg/day, 
however, it can be 10 or 20 mg in 
renal or hepatic dysfunction 
Rosuvastatin Tablets 5, 10, 20 & 40 mg 
5 to 40 mg once daily (max 
starting dose is 20 mg) 
Simvastatin Tablets 
5, 10, 20, 40 & 80 
mg 
Starting from 5 or 10 mg and 
continue with up to 80 mg 
Table 6. Statins used in angina therapy. 
3. New drugs with novel mechanisms of action 
3.1 Ranolazine 
Ranolazine is a piperazine derivative which has been proved as an anti-anginal and anti-
ischemic agent. Although its mode of action is totally different from other anti-anginal 
medications and is not clearly understood, some studies show that ranolazine main 
mechanism in angina is through blockade of late Na current in sarcolemma (late INa). 
In patients with heart failure and chronic angina, in addition to normal Na flow into cells 
there is a late Na ion current which increases intracellular Na levels. Elevated levels of Na in 
the cell influence Ca flow and finally contractility of myocardium, leading to incomplete 
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relaxation and heart muscle dysfunction. Ranolazine by inhibition of late Na current helps 
the ischemic condition to recover (Maier 2009).  
Ralolazine has a variable absorption after oral administration. It is highly metabolized in 
liver and intestine. Ranolazine excreted into both feces and urine.  
This drug is available as extended-release tablets and usually is prescribed 500 to 1000 mg 
once daily (FDA 2006; Dvir and Battler 2010). 
3.2 Nicorandil 
Nicorandil is a nicotinamide ester that is classified as an ATP- sensitive potassium channel 
opener and it has also some nitrate-like activating effects. This medication is a vasodilator 
able to dilate both arterial and venous systems resulting in reduced pre- and afterload. 
Nicorandil's nitrate component is responsible for venous vasodilatation and the arteries and 
arterioles vasodilatation is developed by opening K+ channels. 
This potassium channel agonist is highly absorbed from GI. It is not seriously undergo first-
pass effect thus it is expected to have high bioavailability (75-100%). Its major route of 
elimination is kidneys. 
Gastrointestinal ulceration and discomfort, headache, flushing and weakness have been 
reported to be main adverse reactions to nicorandil (Frydman 1992; Hiremath, Valluru et al. 
2010).  
3.3 Ivabradine 
Ivabradine is the first specific and selective inhibitor of the If channel in the sinus node 
become commercialized (If  is a name for mixed Na+-K+ inward flow). This drug has 
bradycardic effects and lowers the heart rate that may prevent myocardial ischemia and 
angina pectoris; however its pharmacologic benefits have not been proved to be useful in 
the whole patients suffering from stable angina. It may be used in patients who have beta-
blockers intolerance. 
Ivabradine is being absorbed completely and has a bioavailability around 40% due to first-
pass effect. Its elimination is mainly through hepatic metabolism. 
Since the f channels are located in the retina as well, the major side effects accompanying 
ivabradine consumption are visual symptoms like headache, dizziness and luminous/visual 
phenomenon. Thus, ivabradine may influence driving task (Macher and Levy 2009; Dvir 
and Battler 2010; Farrer 2010; Fernandez, Tandar et al. 2010). 
3.4 Trimetazidine 
Trimetazidine is a metabolic agent which is considered as the first cytoprotective anti-
ischemic compound. This drug inhibits fatty acid metabolism by partially blocking 3-
ketoacyl CoA thiolase. And by this means, enhances the glucose consumption of 
myocardium, exactly opposed to what happened in ischemia. Therefore, increased glucose 
oxidation will result in decreased oxygen demand.  
Trimetazidine is widely used outside North America as an effective agent for treatment of 
stable angina; however it is not proved to be used in US (Di Napoli and Taccardi 2009; 
Fernandez, Tandar et al. 2010). 
3.5 Fasudil 
Fasudil is a potent rho-kinase inhibitor, Ca+ antagonist and vasodilator. Inhibiting rho-
kinase will influence the contractility of vascular smooth muscle. 
www.intechopen.com
 
Angina Pectoris 86
One of indications of fusadil is in adjunct therapy of vasospasdic and stable angina (Vicari, 
Chaitman et al. 2005).  
More anti-anginal drugs are under development and further studies and longer follow ups 
are required to establish their place in treatment of patients with coronary artery disease.       
4. Current researches 
Traditional therapies for angina pectoris have focused largely on heart rate reduction and 
coronary vasodilation. On the other hand, considering the pharmaceutical aspect, the 
conventional dosage forms are not sufficient for all medications and in some cases there are 
progressive demands on novel drug formulations to reduce the dose intervals, to obtain 
drug levels constant in patients' blood and release the medication following biological 
rhythm. Additionally, route of administration plays an important role in efficacy and even 
toxicity of the drug. 
4.1 Timed-release drug delivery system 
Drug delivery systems (DDS) that can precisely control the release rates have had an 
enormous impact on the health care system. Of this category controlled-release or sustained-
release drug delivery systems are one of the most beneficial and advantageous drug 
delivery technologies that are used in particular medications to control their release. In the 
last two decades there has been a remarkable improvement in the field of novel drug 
delivery systems. Carrier technology offers an intelligent approach for drug delivery by 
coupling the drug to a carrier particle such as microspheres, nanoparticles, liposomes, etc, 
which modulates the release and absorption characteristics of the drug (Vasir, Tambwekar 
et al. 2003; Dehghan, Aboofazeli et al. 2010).  
The candidates for being embedded in these systems should meet some qualifications, of 
which, short half life, narrow therapeutic index and high first-pass effect can be mentioned. 
As it was shown previously in this chapter, there are several timed-controlled formulations 
available for use in angina therapy. 
4.2 Pulsatile drug delivery system 
It has been proved that in cardiovascular disease there are some morning increases in 
capillary resistance, vascular reactivity and platelet agreeability which decrease latter in the 
day. Therefore, there is a higher possibility (or risk) of myocardial infarction and sudden 
cardiac death before noon rather than evening. Furthermore, the obtained data from several 
studies show that the time of medication administration can influence its pharmacodynamic 
and pharmacokinetic.  
Considering these facts, scientists have developed a novel drug delivery system named 
pulsatile drug delivery based on chronobiology in which drug is released from supporting 
carriers in response to different stimuli. The carriers can react to pH, temperature, magnetic or 
electric field, ultrasound, light and mechanic forces. Carriers are usually polymers which own 
certain characteristics such as safety, biocompatibility ability to respond to external stimuli. 
There are some FDA approved chronotherapeutic products. Verapamil and propranolol are 
two samples of this category which is specifically designed to lower morning increased 
blood pressure. In the near future, there will be medications possessing this technology for 
treatment of angina (portaluppi, 2007 & Mandal, 2010).   
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5. Conclusion 
Decades of research in these fields results in promising achievements. Still there are several 
studies aiming to develop new agents with novel mechanisms of action, to develop agents 
overcoming the problems and limitations of traditional and conventional medications and 
or their dosage forms more, to carry clinical trials focusing on combination therapy for 
reduction of adverse effects and finally to select the new agents which have mortality benefit 
when added to standard therapy. 
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